InvestorsHub Logo
Followers 94
Posts 11282
Boards Moderated 0
Alias Born 11/02/2003

Re: holycow post# 17002

Wednesday, 03/02/2005 10:41:31 PM

Wednesday, March 02, 2005 10:41:31 PM

Post# of 64738
Holycow cygx expected to do this in-life proof-of-principle ,IMHO they were pleasantly surprised and proud that such a small dose of their product works ,and this small dose affects the virus, what will a greater dose do? Cytogenix knows this is great news ,we the public tend to dissect a PR to the point where we turn a positive into a negative .Again lets not scare each other out of our future.


Dr. Malcolm Skolnick, CytoGenix president and CEO, commented, "This is the first in a series of in-life proof-of-principle data we expected based on our earlier observations in cell culture where Simplivir(TM) reduced viral titer load up to 500-fold. These data extend the validation of CytoGenix' proprietary delivery method for topical administration of plasmid DNA-based therapeutics."

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.